More Information Product Details Synonyms Product Type Properties Formula MW Merck Index CAS Purity Chemicals Appearance Solubility Identity InChi Key Shipping and Handling Shipping Short Term Storage Long Term Storage Use/Stability Documents MSDS Product Specification Sheet Datasheet

BRL 49653C; Rosiglitazone XR; Avandia

Chemical

C18H19N3O3S . C4H4O4

357.4 . 116.1

14: 8265

155141-29-0

≥98% (NMR)

White to off-white powder.

Soluble in ethanol or buffered aqueous solutions with pH 2.3.

Determined by IR and 1H-NMR.

SUFUKZSWUHZXAV-BTJKTKAUSA-N

AMBIENT

+4°C

+4°C

Stable for at least 2 years after receipt when stored at +4°C.Stock solutions are stable for at least 3 months when stored at -20°C.

Download PDF

Download PDF

• Same activities as rosaglitazone (Prod. No. AG-CR1-3570) but different formulation.
• Antidiabetic, hypoglycemic agent [1, 5].
• Potent and selective peroxisome proliferator-activated receptor γ (PPAR-γ) agonist [2, 3].
• Potent insulin sensitizing agent binding to the PPAR receptors in fat cells and making the cells more responsive to insulin. Ameliorates insulin resistance [4-6, 8].
• Improves blood pressure and vascular function [7].
• Enhances proliferation of endogenous neural progenitor cells (NPCs) [9].
• Anti-inflammatory compound [10, 11].
• Has controversial therapeutic effects on the cardiovascular system [12].
• Promotes adipocyte differentiation of mesenchymal stem cells (MSCs) [13].

Product References

[[ω-(Heterocyclylamino)alkoxy]benzyl]-2,4-thiazolidinediones as potent antihyperglycemic agents: B.C. Cantello, et al.; J. Med. Chem. 37, 3977 (1994)

An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ): J.M. Lehmann, et al.; J. Biol. Chem. 270, 12953 (1995)

Rosiglitazone: J.A. Balfour & G.L. Plosker; Drugs 57, 921 (1999) (Review)

Differential effects of insulin-sensitizers troglitazone and rosiglitazone on ion currents in rat vascular myocytes: G.A. Knock, et al.; Eur. J. Pharmacol. 368, 103 (1999)

Rosiglitazone: an agent from the thiazolidinedione class for the treatment of type 2 diabetes: A. Cheng-Lai & A. Levine; Heart Dis. 2, 326 (2000) (Review)

Rosiglitazone in the treatment of type 2 diabetes mellitus: a critical review: J.M. Malinowski & S. Bolesta; Clin. Ther. 22, 1151 (2000) (Review)

PPAR(gamma) agonist rosiglitazone improves vascular function and lowers blood pressure in hypertensive transgenic mice: M.J. Ryan, et al.; Hypertension 3, 661 (2004)

Rosiglitazone: a review of its use in type 2 diabetes mellitus: E.D. Deeks & S.J. Keam; Drugs 67, 2747 (2007) (Review)

Rosiglitazone enhances the proliferation of neural progenitor cells and inhibits inflammation response after spinal cord injury: Q.Q. Meng, et al.; Neurosci. Lett. 503, 191 (2011)

Inhibitory effects of rosiglitazone on lipopolysaccharide-induced inflammation in a murine model and HK-2 cells: W.M. Wang, et al.; Am. J. Nephrol. 34, 152 (2011)

PPARγ agonist rosiglitazone ameliorates LPS-induced inflammation in vascular smooth muscle cells via the TLR4/TRIF/IRF3/IP-10 signaling pathway: Y. Ji, et al.; Cytokine 55, 409 (2011)

PPARγ activator, rosiglitazone: Is it beneficial or harmful to the cardiovascular system? S. Palee, et al.; World J. Cardiol. 3, 144 (2011)

Rosiglitazone-induced adipogenesis in a bone marrow mesenchymal stem cell line: D. Wang, et al.; Biomed. Sci. Instrum. 47, 213 (2011)

>>> 更多资讯详情请访问蚂蚁淘商城